Literature DB >> 8305836

Guillain-Barré syndrome following streptokinase therapy.

R Kaiser1, R Kaufmann, M Czygan, H Lang, C H Lücking.   

Abstract

Clinical and laboratory data from a patient with Guillain-Barré syndrome indicated a probable etiological correlation of polyradiculitis to the intravenous administration of streptokinase. Oligoclonal IgG bands in the cerebrospinal fluid and serum were shown to be specific for streptokinase. Serum titers of streptokinase were elevated 64-fold for IgG, 16-fold for IgM, and 4-fold for IgA compared to controls. Clinical symptoms of Guillain-Barré syndrome are thought to result from streptokinase antibody complex mediated damage to the local blood-nerve barrier. The pathogenic relevance of autoantibodies to albumin and proteins of the central and peripheral nervous systems, occurring early after onset of symptoms, remains to be determined.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8305836     DOI: 10.1007/BF00190321

Source DB:  PubMed          Journal:  Clin Investig        ISSN: 0941-0198


  17 in total

1.  The peripheral myelin glycoprotein P0 expresses the L2/HNK-1 and L3 carbohydrate structures shared by neural adhesion molecules.

Authors:  E Bollensen; M Schachner
Journal:  Neurosci Lett       Date:  1987-11-10       Impact factor: 3.046

2.  Disseminated vasculomyelinopathy in the peripheral nervous system mediated by immune complexes (ICs). Immunohistochemical studies of sciatic nerves in chronic serum sickness (CHSS) in rabbits.

Authors:  S Krajewski; M Szablowska-Krajewska
Journal:  J Neurol Sci       Date:  1986-02       Impact factor: 3.181

3.  Protein transfer at the blood cerebrospinal fluid barrier and the quantitation of the humoral immune response within the central nervous system.

Authors:  H Reiber; K Felgenhauer
Journal:  Clin Chim Acta       Date:  1987-03-30       Impact factor: 3.786

4.  Guillain-Barré syndrome after streptokinase therapy.

Authors:  M J Cicale
Journal:  South Med J       Date:  1987-08       Impact factor: 0.954

5.  Oligoclonal IgG bands in cerebrospinal fluid. Methodological and clinical aspects.

Authors:  V K Kostulas
Journal:  Acta Neurol Scand Suppl       Date:  1985

6.  Local production of mumps IgG and IgM antibodies in the cerebrospinal fluid of meningitis patients.

Authors:  P Ukkonen; M L Granström; J Räsänen; E M Salonen; K Penttinen
Journal:  J Med Virol       Date:  1981       Impact factor: 2.327

7.  Complement-fixing antiperipheral nerve myelin antibodies in patients with inflammatory polyneuritis and with polyneuropathy and paraproteinemia.

Authors:  N Latov; R B Gross; J Kastelman; T Flanagan; S Lamme; D A Alkaitis; M R Olarte; W H Sherman; L Chess; A S Penn
Journal:  Neurology       Date:  1981-12       Impact factor: 9.910

8.  Affinity immunoblotting: rapid and sensitive detection of oligoclonal IgG, IgA and IgM in unconcentrated CSF by agarose isoelectric focusing.

Authors:  R Kaiser
Journal:  J Neurol Sci       Date:  1991-06       Impact factor: 3.181

9.  Serum antibodies to gangliosides in Guillain-Barré syndrome.

Authors:  A A Ilyas; H J Willison; R H Quarles; F B Jungalwala; D R Cornblath; B D Trapp; D E Griffin; J W Griffin; G M McKhann
Journal:  Ann Neurol       Date:  1988-05       Impact factor: 10.422

10.  Anti-peripheral myelin antibody in patients with demyelinating neuropathy: quantitative and kinetic determination of serum antibody by complement component 1 fixation.

Authors:  C L Koski; R Humphrey; M L Shin
Journal:  Proc Natl Acad Sci U S A       Date:  1985-02       Impact factor: 11.205

View more
  2 in total

1.  Occurrence of Guillain-Barré syndrome as an immune mediated complication after thrombolysis with streptokinase for acute anterior wall myocardial infarction: a caution to be vigilant.

Authors:  Basant Kumar; Navin Agrawal; Soumya Patra; C N Manjunath
Journal:  BMJ Case Rep       Date:  2013-10-07

2.  Guillain-barré syndrome after thrombolysis with streptokinase.

Authors:  Ertugrul Okuyan; Mehmet Akif Cakar; Mustafa H Dinckal
Journal:  Cardiol Res Pract       Date:  2010-12-26       Impact factor: 1.866

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.